Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. , May 21, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,293,159 titled “Measuring the ‘on-skin’ time of a Transcutaneous Electrical Nerve Stimulator (TENS) device in order to minimize
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. , May 07, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,279,179 titled “Transcutaneous Electrical Nerve Stimulator with automatic detection of user sleep-wake state.” The patent covers
View HTML
Toggle Summary NeuroMetrix Reports Q1 2019 Financial Results
WALTHAM, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ), today reported financial and business highlights for the quarter ended March 31, 2019 . The Company develops and markets novel therapies for chronic health conditions employing neurostimulation and digital
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for First Quarter 2019 Financial Results Conference Call
WALTHAM, Mass. , April 17, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 first quarter financial results before the opening of the market on Thursday, April 25, 2019. The Company will host a conference call at 8:00 a.m., Eastern
View HTML
Toggle Summary NeuroMetrix Reports New Clinical Studies Published on DPNCheck
WALTHAM, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported publication of three new DPNCheck ® clinical studies. DPNCheck is a point-of-care test that provides accurate and cost-effective screening, diagnosis and monitoring of diabetic peripheral neuropathy
View HTML
Toggle Summary NeuroMetrix Reports Q4 and Full Year 2018 Financial Results
WALTHAM, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter and year ended December 31, 2018 . The Company develops and markets novel therapies for chronic health conditions employing neurostimulation and
View HTML
Toggle Summary NeuroMetrix Reports Publication of Randomized Controlled Trial of Quell Wearable Pain Relief in Chronic Low Back Pain
WALTHAM, Mass. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) today reported publication of results from a randomized controlled trial of Quell ® in subjects with chronic low back pain in the journal Pain Practice.  The paper is titled “ Outcome of a High Frequency
View HTML
Toggle Summary Quell Reports Successful CES 2019
WALTHAM, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix (Nasdaq: NURO) today announced a successful CES 2019, the world’s largest and most influential technology event, which took place January 8 – 11 in Las Vegas.  Highlights of the week-long event include: Quell 2.0 Named CES Innovation
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Fourth Quarter 2018 Financial Results Conference Call
WALTHAM, Mass. , Jan. 15, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ: NURO) will issue its fourth quarter 2018 financial results on Thursday morning January 24, 2019 . A conference call will be held shortly afterwards at 8:00 a.m. Eastern. The call may be accessed in the United States at
View HTML
Toggle Summary Quell Named CES 2019 Innovation Awards Honoree
WALTHAM, Mass. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced that it has been named a CES ® 2019 Innovation Awards Honoree for Quell ® 2.0 Wearable Pain Relief Technology™ in the Fitness, Sports and Biotech product category.
View HTML